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Introduction
What is Schizophrenia (SCZ)?
• Chronic & debilitating neurobehavioral disorder
• Affects estimated 21 million people worldwide (WHO Statistics Sheet, 2018)
• Age at onset observed in adolescence or early adulthood
• Diagnosis based on clinical observation or self-reporting (Gejman et al., 2010)
• Costs U.S. approx. $62 billion annually for medications & other 
therapeutic expenses
Current Treatment 
• Antipsychotic Medications 
• Typical – dopamine D2 antagonists (e. g. Haloperidol)
• Attempts to treat associated positive symptoms
• Atypical – dopamine D2 antagonists; act on histamine, 
norepinephrine, & serotonin (e. g. Clozapine, Olanzapine, & 
Risperidone)
• Attempts to treat associated positive & negative symptoms
• Psychosocial Interventions
• Individual & family therapy, social skills training, and vocational 
rehabilitation 
Problems with Current Treatment
• Typical antipsychotic drugs (FGA)
• Not designed to treat (-) symptoms
• Potent extrapyramidal motor side effects
• Atypical antipsychotic drugs (SGA)
• Dose-dependent side effects (Solmi et al., 2017)
Weight gain, insulin resistance/diabetes, cognitive impairment, 
agranulocytosis, seizures, pneumonia, myocarditis, & 
hypersalivation.
• Short time to discontinuation
Haloperidol
Clozapine
Neuroinflammatory Aspect
• SCZ patients shown to have increased 
inflammation in CNS (Howes & McCutcheon, 2017; Van 
Kesteren et al., 2017)
Image adapted from Harvard Health Publishing 
PFC
Image adapted from Bloomfield et al., 2016
Tumor Necrosis Factor-alpha (TNFα)
• Pro-inflammatory cytokine
• Implicated in some autoimmune diseases (ex. RA)
• Influence state of CNS defense cells, called microglia
Image from MEDBULLETS:STEP 1
Microglial Cells
• Primary immune cells of the CNS & scan local environment for cellular stress 
(Nimmerjahn et al., 2005)
• Normally exist as anti-inflammatory, neuroprotective agents (M2 state)
• Upon activation by TNFα secretion, switch to M1 state, which is pro-inflammatory &
neurotoxic
• Activated M1 microglia leads to overexpression of pro-inflammatory cytokines (ex. 
TNFα) & ROS, resulting in synaptic loss & neuronal death (Howes & McCutcheon, 2017)
P2D Bioscience, Inc. 
TNFα Modulator Development
• Isoindoline-derived compounds
• PD2024 & PD340
• Small, anti-TNF molecules
• Destabilizes TNFα mRNA
• Decreases TNFα protein release & secretion 
• Centrally-acting, anti-neuroinflammatory properties
• Safe & well tolerated in small (rats) and large (dogs) animals
PD2024
Mw = 179.0 g/mol
TNFα IC50 = 3 μM
Polyinosinic:polycytidylic Acid (Poly I:C)
• Immunostimulant
• Interaction with TLR3
• Synthetic dsRNA (virus-like)
• Activates innate immune system
• Mimics neonatal infection in humans
Image from: https://www.biomol.com/product_Polyinosinic-polycytidylic-Acid-potassium-salt.html?aRelated=Cay16881
Poly I:C Rodent Model of SCZ
• Behavioral deficits/neuropathology consistent with SCZ
• Sensorimotor gating  
• Cognitive 
• Dopamine hyperfunction
• Structural abnormalities (cortical volume reduction in PFC & HPC) 
(Meyer, 2014)
• Symptoms emerge in offspring, reflects delayed onset as seen 
in humans
• Clozapine & Risperidone alleviate deficits in neonatally 
treated poly I:C rats
Hypotheses
1. Treatment with Poly I:C will increase TNFα protein levels similar to 
the neuroinflammatory response for individuals diagnosed with 
schizophrenia
2. Novel TNFα modulators will alleviate sensorimotor gating deficits
of the rodent Poly I:C model 
3. Novel TNFα modulators will reduce associated neuroinflammation
via a decrease in microglial cell activation levels in the HPC and 
PFC, two brain areas that mediate sensorimotor gating
Experimental Design
Study Design: Experiment 1 – TNFα Protein Levels
• A total of 17 male Sprague-Dawley pups IP injected with either Poly 
I:C (2 mg/kg) or saline (0.9% NaCl) from P5-7
• Sacrificed at P30 (in accordance with Exp. 2 & 3 dietary manipulation)
• PFC & HPC dissected away
• Tissue subjected to TNFα ELISA kit (Biomatik, Inc.; Wilmington, 
DE)
• Protein detection via colorimetric detection (450 nm)
Study Design: Experiment 2 – PD2024
Grouping & Conditions
• SD pups divided equally into 4 groups
(Poly I:C/Control, Poly I:C/PD2024, Saline/Control, Saline/PD2024)
• Poly I:C groups IP injected with Poly I:C (2 mg/kg) from P5-7
• Saline groups IP injected with saline (0.9% NaCl) from P5-7
• All animals weaned at P21, dietary manipulation began at P30
• PD2024 groups received PD2024 until P67
• Control groups received a normal diet until P67
Study Design: Experiment 3 – PD340
Grouping & Conditions
• SD pups divided equally into 6 groups
(Poly I:C/Control, Poly I:C/PD340 – 10 mg/kg, Poly I:C/PD340 – 30 mg/kg, 
Saline/Control, Saline/PD340 – 10 mg/kg, Saline/PD340 – 30 mg/kg)
• Poly I:C groups IP injected with Poly I:C (2 mg/kg) from P5-7
• Saline groups IP injected with saline (0.9% NaCl) from P5-7
• All animals weaned at P21, dietary manipulation began at P30
• PD340 groups received PD340 (10 mg/kg or 30 mg/kg) until P67
• Control groups received a normal diet until P67
Study Design: Experiments 2 & 3
Prepulse Inhibition (PPI)
• Behaviorally tested on PPI
• During adolescence (P44-46) and adulthood (P60-66)
Sacrifice & Immunohistochemistry (IHC)
• Sacrificed at P67, PFC & HPC dissected away, subjected to IHC
• IHC examined microglial cell activation using the Iba1-GFP conjugated 
antibody system
Prepulse Inhibition (PPI)
Used to measure 
auditory 
sensorimotor gating 
Image from: https://en.wikipedia.org/wiki/Prepulse_inhibition#/media/File:Prepulse_Inhibition_schematically.png
Immunohistochemistry (IHC)
Detection technique, selectively 
identifies protein(s) in cells
Image from Exp. 3 
Results
Figure 1. TNFα Protein Levels Following Saline or 
Poly I:C Administration Between P33-35.
Figure 2. Experiment 2: PPI Performance in 
Adolescents and Adults.
Figure 3. Experiment 2: 
Microglial Cell 
Activation in the PFC 
and HPC.
Figure 4. Experiment 2: 
Representative Images 
of Iba1-GFP Labeled 
Microglia Cells in the 
PFC.
Poly I:C/Control Poly I:C/PD2024
Saline/PD2024Saline/Control
Figure 5. Experiment 3: PPI Performance for 
Adolescents and Adults.
Figure 6. Experiment 3: Microglial Cell 
Activation in the PFC and HPC.
Conclusions & Future 
Directions
Conclusions
• Neonatal Poly I:C resulted in behavioral deficits in adolescence & 
adulthood, consistent with clinical observation & diagnosis of SCZ.
• Two novel TNF-alpha modulators (PD2024 & PD340) alleviated
sensorimotor gating deficits in adolescence and adulthood.
• Decreased microglial cell activation known to mediate sensorimotor gating
Future Work & Directions
• PD2024 and PD340 adjunctively used with antipsychotic drugs in the 
Poly I:C and other rodent models of SCZ. 
Acknowledgements
Thesis Committee
Dr. Russell Brown (Chair)
Dr. Gregory Ordway 
Dr. Donald Hoover
P2D Bioscience, Inc.
Dr. Prasad Gabbita
Graduate Students
Drew Gill
Rudy Chapman
Kyle Travis
Amanda Smith
Trevor Chapman
Brown Lab
GPSA
David Moore (GPSA Advisor)
GPSA membership
School of Graduate Studies
Dr. Sharon McGee 
Dr. Karin Bartoszuk 
Emily Redd
References
Journal
Bloomfield P S, Selveraj S, Veronese M, Rizzo G, Bertoldo A, Owen D R et al. (2016). “Microglial Activity in People at Ultra High Risk of Psychosis and Schizophrenia: An (11C) PBR28 PET Brain Imaging Study.” The American Journal of 
Psychiatry 173, Image.
Brymer K J, Romay-Tallon R, Allen J, Caruncho H J, Kalynchuk L E (2019). “Exploring the Potential Antidepressant Mechanisms of TNFα Antagonists.” Frontiers in Neuroscience 13:98. 
Egerton A, Brugger S, Raffin M et al. (2012). “Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia.” Neuropsychopharmacology 37: 2515-2521.
Gabbita S P, Johnson M F, Kobritz N, Eslami P, Poteshkina A, Varadarajan S et al. (2015). “Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model.” PLoS
One 10: e0137305.
Garrett M, Silva R (2003). “Auditory Hallucinations, Source Monitoring, and the Belief that “Voices” are Real.” Schizophrenia Bulletin 29: 445-457.
Gejman P V, Sanders A R, Duan J (2010). “The Role of Genetics in the Etiology of Schizophrenia.” Psychiatric Clinics of North America 33(1): 35-66.
Giovanoli S, Engler H, Engler A, Richetto J, Feldon J, Riva M A et al. (2016). “Preventive Effects of Minocycline in a Neurodevelopmental Two-Hit Model with Relevance to Schizophrenia.” Translational Psychiatry 6: e772.
Harvard Mental Health Letter (2011). “How Addiction Hijacks the Brain.” Harvard Health Publishing Harvard Medical School, Image. 
Howes O D, Kapur S (2009). “The Dopamine Hypothesis of Schizophrenia: Version III — The Final Common Pathway.” Schizophrenia Bulletin 35: 549-556.
Howes O D, McCutcheon R (2017). “Inflammation and the Neural Diathesis-Stress Hypothesis of Schizophrenia: A Reconceptualization.” Translational Psychiatry 7: 1-11.
Johnson K M, Jones S M (1990). “Neuropharmacology of Phencyclidine: Basic Mechanisms and Therapeutic Potential.” Annual Review of Pharmacology and Toxicology 30: 707-750.
Kusumi I, Boku S, Takahashi Y (2014). “Psychopharmacology of Atypical Antipsychotic Drugs: From the Receptor Binding Profile to Neuroprotection and Neurogenesis.” Psychiatry and Clinical Neurosciences 69(5): 243-258
Lavretsky H (2008). “Chapter 1: History of Schizophrenia as a Psychiatric Disorder.” Clinical Handbook of Schizophrenia Guilford Publications: 3-12. 
McCusker R H, Kelley K W (2013). “Immune-Neural Connections: How the Immune System’s Response to Infectious Agents Influences Behavior.” Journal of Experimental Biology 216(Pt 1): 84-98.
Meyer U (2014). “Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems.” Biological Psychiatry 75: 307-315
Miller B J, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011). “Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects.” Biological Psychiatry 70: 663-671.
Nimmerjahn A, Kirchhoff F, Helmchen F (2005). “Resting Microglial Cells are Highly Dynamic Surveillants of Brain Parenchyma In Vivo.” Science 308(5726): 1314-1318.
Perry V H (1998). “A Revised View of the Central Nervous System Microenvironment and Major Histocompatibility Complex Class II Antigen Presentation.” Journal of Neuroimmunology 90: 113-121.
Ransohoff R M (2016). “How Neuroinflammation Contributes to Neurodegeneration.” Science 353(6301): 777-783.
Schroeter M, Dennin M A, Walberer M, Backes H, Neumaier B, Fink G R et al. (2009). “Neuroinflammation Extends Brain Tissue at Risk to Vital Peri-Infarct Tissue: A Double Tracer [11C]PK11195- and [18F]FDG-PET Study.” Journal of Cerebral 
Blood Flow Metabolism 29(6): 1216-1225.
Seeman P, Chau-Wong M, Tedesco J, Wong K (1975). “Brain Receptors for Antipsychotic Drugs and Dopamine: Direct Binding Assays.” Proceedings of the National Academy of Sciences of the United States of America 72(11): 4376-4380.
Seeman M V, Seeman P (2014). “Is Schizophrenia a Dopamine Supersensitivity Psychotic Reaction?” Progress in Neuropsychopharmacology and Biological Psychiatry 48: 155-160. 
Solmi M, Veronese M, Thapa N, Facchini S, Stubbs B, Fornaro M, Carvalho A F, Correll C V (2017). “Systemic Review and Meta-Analysis of the Efficacy and Safety of Minocycline in Schizophrenia.” CNS Spectrums 22(5): 415-426.
Stone J M, Morrison P D, Pilowsky L S (2007). “Glutamate and Dopamine Dysregulation in Schizophrenia--A Synthesis and Selective Review.” Journal of Psychopharmacology 21: 440-452.
Van Kesteren C F M G, Gremmels H, de Witte L D, Hol E M, Van Gool A R, Falkai P G et al. (2017). “Immune Involvement in the Pathogenesis of Schizophrenia: A Meta-Analysis on Postmortem Brain Studies.” Translational Psychiatry 7: e1075.
Xiang Y Q, Zheng W, Wang S B, Yang X H, Cai D B, Ng C H, Unguari G S, Kelly D L, Xu W Y, Xiang Y J (2017). “Adjunctive Minocycline for Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.” European Neuropsychopharmacology
27(1): 8-18.
Zhang J M, An J A (2009). “Cytokines, Inflammation and Pain.” International Anesthesiology Clinics 45(2): 27-37.
Zhu F, Zheng Y, Liu Y, Zhang X, Zhao J (2014). “Minocycline Alleviates Behavioral Deficits and Inhibits Microglial Activation in the Offspring of Pregnant Mice After Administration of Polyribosinic-Polyribocytidilic Acid.” Psychiatry Research
219(3): 680-686.
Online 
Donaldson L (2018). “Winning the War on Inflammation.” https://psoriatic-arthritis.com/living/winning-war-inflammation/. Visited 03.17.2019.
Mandal A (2019). “What are Cytokines?” https://www.news-medical.net/health/What-are-Cytokines.aspx. Visited 03.17.2019.
World Health Organization (2018). “Schizophrenia.” https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Visited 02.02.2019.
https://step1.medbullets.com/msk/112059/tnf-alpha-inhibitors. Visited 03.17.2019.
https://www.biolegend.com/media_assets/neuroinflammation/microglia_activation.jpg. Visited 03.17.2019.
https://www.ncbi.nlm.nih.gov/books/NBK92434/figure/immunometh.F1/. Visited 03.17.2019.
https://en.wikipedia.org/wiki/Prepulse_inhibition#/media/File:Prepulse_Inhibition_schematically.png. Visited 03.17.2019.
https://reliawire.com/dopamine/. Visited 03.23.2019.
http://www.priory.com/homol/insulin.htm. Visited 03.23.2019.
https://www.biomol.com/product_Polyinosinic-polycytidylic-Acid-potassium-salt.html?aRelated=Cay16881. Visited 03.23.2019.
https://www.semanticscholar.org/paper/PREPULSE-INHIBITION-OF-THE-ACOUSTIC-STARTLE-REFLEX/d2f991a81ab1873445dde6bcea35b6bde13b95c3/figure/0. Visited 03.23.2019.
http://www.nrlc-group.net/procedures-and-facilities/psychophysiology. Visited 03.23.2019.
Questions?
